Krazati withdrawal completed; Wegovy trial meets endpoint for kids ages 6 to 12

RegulatoryrejectedKrazatiWegovyNegative

AI Analysis

Summary

FDA finalized Krazati's withdrawal from second-line colorectal cancer indication. Separately, Wegovy met its primary endpoint in a pediatric trial for children ages 6 to 12.

Clinical Trial Data

Primary Endpoint

Met

Outcome Details

Krazati withdrawal finalized in second-line colorectal cancer

Importance:6/10

Sentiment:

-0.30

FDA withdrawalcolorectal cancerpediatric trialWegovyKrazati

Related Companies

$STTK

Read the original article

Published by Endpoints News on September 8, 2026 3:21 PM

Read Original